Dr. John P. Fezza, MD

Dr. Fezza practices at Center For Sight Surgery Center - Sarasota in Sarasota, Florida.

Dr. Fezza's NPI, 1184715187, was assigned on September 27, 2006. Dr. Fezza graduated from New York Medical College in 1992. Dr. Fezza holds Florida license ME76288.

Dr. Fezza's primary practice is Center for Sight Surgery Center - Sarasota, at 2601 S Tamiami Trl, Sarasota, FL 34239. The practice phone is (941) 925-2020.

Dr. Fezza's primary practice is Center For Sight Surgery Center - Sarasota in Sarasota, Florida. Dr. Fezza is also affiliated with Sarasota Memorial Hospital - Sarasota Campus. Dmand AI also links Dr. Fezza to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fezza practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmic plastic and reconstructive surgery is Dr. Fezza's primary specialty in the NPI Registry, under taxonomy code 207WX0200X. Dr. Fezza is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Fezza's licenses on file in 8 states: Florida, Colorado, Arizona, California, Michigan, Texas, New York and Tennessee.

CMS data shows 556 Medicare services from Dr. Fezza across 5 procedure codes in 2024, for 461 Medicare patients. Medicare paid $180,292 for them.

CMS counts 461 Medicare patients who saw Dr. Fezza in 2024. The largest group is 65 to 74, with 239 patients. 75% of them have high cholesterol, and 69% have high blood pressure. Their average risk score is 0.91, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Fezza's median patient age at 73, with 65% women.

In 2024, Dr. Fezza wrote 1,586 Medicare Part D claims for 563 patients. 98% of them were for generic drugs. CMS names the drug for 1,556 of them, across 9 drugs with 11 or more claims each, at $12,750 in total drug cost. In 2023, CMS named 1,440 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Fezza for performance year 2024, reported as part of a group. Dr. Fezza accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 11 procedures of melanoma (skin cancer) excision by Dr. Fezza, more than 64% of the clinicians it reports for that procedure.

Dmand AI links 29 papers to Dr. Fezza, published from 2016 to 2024. 2023 was the busiest year, with 3. The most frequent topics are Skin Aging, Botulinum Toxins, Type A and Cosmetic Techniques. Dr. Fezza has published most often in Ophthalmic Plast Reconstr Surg. Dr. Fezza's most frequent co-authors are Julie Ann Woodward, MD, Sheila Chang Barbarino, MD and Guy Gourgy Massry, MD.

CMS Open Payments shows 3,934 general payments to Dr. Fezza from 18 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 58% of the total. Allergan Inc. paid the most, $2,146,383. It also lists 5 research payments totaling $26,185 from 2016 to 2023.

Dmand AI lists 3 awards for Dr. Fezza, most recently Sarasota Magazine: Top Doctors in 2014.

Dr. Fezza graduated from New York Medical College in 1992. Dr. Fezza is a member of AAO.

Dr. Fezza is in network with 9 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.